The FDA approved the AngioJet ZelanteDVT thrombectomy catheter on Nov. 30 to treat patients with deep vein thrombosis. The catheter also received a CE Mark on the same day for approval in Europe.
The ZelanteDVT catheter offers four times the removal power of large venous clot burdens compared with previous AngioJet catheters, according to Boston Scientific, which manufactures the catheter.
As many as 2.5 million people each year in the U.S. and Europe suffer from deep vein thrombosis, which occurs when a blood clot forms in at least one deep vein.
Boston Scientific said the ZelanteDVT thrombectomy set is intended for use with the AngioJet Ultra Console and the AngioJet Power Pulse.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.